JP2009535344A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009535344A5 JP2009535344A5 JP2009507823A JP2009507823A JP2009535344A5 JP 2009535344 A5 JP2009535344 A5 JP 2009535344A5 JP 2009507823 A JP2009507823 A JP 2009507823A JP 2009507823 A JP2009507823 A JP 2009507823A JP 2009535344 A5 JP2009535344 A5 JP 2009535344A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- alkyl
- compound
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 59
- 125000003118 aryl group Chemical group 0.000 claims description 42
- 150000001875 compounds Chemical class 0.000 claims description 36
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 32
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 28
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 26
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 25
- -1 silylthio Chemical group 0.000 claims description 24
- 150000002431 hydrogen Chemical class 0.000 claims description 22
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 18
- 125000003435 aroyl group Chemical group 0.000 claims description 18
- 125000004104 aryloxy group Chemical group 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 125000001475 halogen functional group Chemical group 0.000 claims description 18
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 18
- 125000004423 acyloxy group Chemical group 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 16
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 16
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 15
- 125000002252 acyl group Chemical group 0.000 claims description 14
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 claims description 13
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 125000002947 alkylene group Chemical group 0.000 claims description 12
- 125000000304 alkynyl group Chemical group 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- CTQJAETYIVEEFX-UHFFFAOYSA-N [N-]=[N+]=NN(N)N=[N+]=[N-] Chemical compound [N-]=[N+]=NN(N)N=[N+]=[N-] CTQJAETYIVEEFX-UHFFFAOYSA-N 0.000 claims description 10
- 125000004450 alkenylene group Chemical group 0.000 claims description 10
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 10
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 10
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims description 10
- 125000005353 silylalkyl group Chemical group 0.000 claims description 10
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 10
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 10
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 10
- 125000004001 thioalkyl group Chemical group 0.000 claims description 10
- 125000005000 thioaryl group Chemical group 0.000 claims description 10
- 150000003573 thiols Chemical class 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 8
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 8
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 claims description 8
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 8
- 150000003462 sulfoxides Chemical class 0.000 claims description 8
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 6
- 101150024084 nhr-28 gene Proteins 0.000 claims description 6
- 230000009286 beneficial effect Effects 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 102000047174 Disks Large Homolog 4 Human genes 0.000 claims description 4
- 108700019745 Disks Large Homolog 4 Proteins 0.000 claims description 4
- 102000004874 Synaptophysin Human genes 0.000 claims description 4
- 108090001076 Synaptophysin Proteins 0.000 claims description 4
- 125000005518 carboxamido group Chemical group 0.000 claims description 4
- 230000006735 deficit Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 4
- 230000003827 upregulation Effects 0.000 claims description 4
- ASVQCPUSQNFHHU-UHFFFAOYSA-N 4-methyl-6-phenyl-3-(4-pyrimidin-2-ylpiperazin-1-yl)pyridazine Chemical compound CC1=CC(C=2C=CC=CC=2)=NN=C1N(CC1)CCN1C1=NC=CC=N1 ASVQCPUSQNFHHU-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 102000004257 Potassium Channel Human genes 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 108020001213 potassium channel Proteins 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- ZPJGUEPHFXPAQF-UHFFFAOYSA-N 6-phenyl-4-pyridin-4-yl-3-(4-pyrimidin-2-ylpiperazin-1-yl)pyridazine Chemical compound C1CN(C=2C(=CC(=NN=2)C=2C=CC=CC=2)C=2C=CN=CC=2)CCN1C1=NC=CC=N1 ZPJGUEPHFXPAQF-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 0 Cc1c(*)c(*)c(*)c(C*)c1C(C(O*)=C1)=IIN=C1N1C(*)C(*)N(*)C(*)C1* Chemical compound Cc1c(*)c(*)c(*)c(C*)c1C(C(O*)=C1)=IIN=C1N1C(*)C(*)N(*)C(*)C1* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79632806P | 2006-04-28 | 2006-04-28 | |
| PCT/US2007/010248 WO2007127375A2 (en) | 2006-04-28 | 2007-04-27 | Formulations containing pyridazine compounds for treating neuroinflammatory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009535344A JP2009535344A (ja) | 2009-10-01 |
| JP2009535344A5 true JP2009535344A5 (enExample) | 2011-06-16 |
Family
ID=38626233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009507823A Pending JP2009535344A (ja) | 2006-04-28 | 2007-04-27 | 神経炎症性疾患の処置のためのピリダジン化合物を含む処方物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20090325973A1 (enExample) |
| EP (1) | EP2063894B1 (enExample) |
| JP (1) | JP2009535344A (enExample) |
| CN (1) | CN101754762A (enExample) |
| AU (1) | AU2007243280A1 (enExample) |
| BR (1) | BRPI0710938A2 (enExample) |
| CA (1) | CA2650625A1 (enExample) |
| IL (1) | IL194968A0 (enExample) |
| MX (1) | MX2008013843A (enExample) |
| WO (1) | WO2007127375A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1430033A4 (en) | 2001-08-31 | 2004-12-15 | Univ Northwestern | ANTI-INFLAMMATORY AND PROTEIN-INK-INHIBITING COMPOSITION AND THEIR USE |
| JP5337375B2 (ja) | 2004-11-02 | 2013-11-06 | ノースウェスタン ユニバーシティ | ピリダジン化合物、組成物および方法 |
| WO2006050359A2 (en) | 2004-11-02 | 2006-05-11 | Northwestern University | Pyridazine compounds and methods |
| CA2650711A1 (en) | 2006-04-28 | 2007-11-08 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
| CA2650625A1 (en) | 2006-04-28 | 2007-11-08 | Northwestern University | Formulations containing pyridazine compounds for treating neuroinflammatory diseases |
| PE20090188A1 (es) | 2007-03-15 | 2009-03-20 | Novartis Ag | Compuestos heterociclicos como moduladores de la senda de hedgehog |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| US20100227793A1 (en) * | 2009-03-04 | 2010-09-09 | Scott Thomas Brady | Compositions and Methods for Treating Amyotrophic Lateral Sclerosis |
| JP5894540B2 (ja) | 2010-02-18 | 2016-03-30 | ブイティーブイ・セラピューティクス・エルエルシー | フェニル−ヘテロアリール誘導体とその使用の方法 |
| WO2011156901A2 (en) * | 2010-06-17 | 2011-12-22 | Waratah Pharmaceuticals Inc. | Compounds, compositions and methods for treatment of multiple sclerosis |
| WO2012031383A1 (zh) | 2010-09-06 | 2012-03-15 | 中国科学院广州生物医药与健康研究院 | 酰胺类化合物 |
| EP2771325B1 (en) * | 2011-10-28 | 2017-06-28 | Inhibitaxin Limited | Pyridazine derivatives useful in therapy |
| TW202413340A (zh) | 2016-07-12 | 2024-04-01 | 美商銳新醫藥公司 | 作為異位shp2抑制劑之2,5-雙取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪 |
| RU2019126455A (ru) | 2017-01-23 | 2021-02-24 | Революшн Медсинз, Инк. | Пиридиновые соединения в качестве аллостерических ингибиторов shp2 |
| SG11201906209SA (en) | 2017-01-23 | 2019-08-27 | Revolution Medicines Inc | Bicyclic compounds as allosteric shp2 inhibitors |
| EP3678703A1 (en) | 2017-09-07 | 2020-07-15 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| JP2020536881A (ja) * | 2017-10-12 | 2020-12-17 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としてのピリジン、ピラジンおよびトリアジン化合物 |
| RU2020123241A (ru) | 2017-12-15 | 2022-01-17 | Революшн Медсинз, Инк. | Полициклические соединения в качестве аллостерических ингибиторов shp2 |
| US20250195517A1 (en) * | 2022-02-23 | 2025-06-19 | Immunochem Therapeutics, Llc | Treatment of intracranial hemorrhage |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL92451C (enExample) * | 1955-08-19 | |||
| GB1345880A (en) * | 1971-06-18 | 1974-02-06 | Cepbepe | Pyridazine derivatives |
| FR2510998B1 (fr) | 1981-08-07 | 1986-01-10 | Sanofi Sa | Nouveaux derives amines de la pyridazine, leur procede de preparation et les medicaments, a action desinhibitrice, qui en comportent |
| FR2511366A1 (fr) * | 1981-08-11 | 1983-02-18 | Sanofi Sa | Nouveaux derives de la pyridazine, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent |
| DE3217325A1 (de) | 1982-05-08 | 1983-11-10 | Hoechst Ag, 6230 Frankfurt | 3-amino-6-aryl-1,2,4-triazolo(4,3-b)-pyridazine, ihre herstellung und ihre verwendung |
| FR2540113A1 (fr) * | 1983-01-27 | 1984-08-03 | Sanofi Sa | Acides derives de la pyridazine actifs sur le systeme nerveux central |
| ES8802151A1 (es) | 1985-07-31 | 1988-04-01 | Janssen Pharmaceutica Nv | Un procedimiento para la preparacion de nuevos piridazinaminas. |
| US4654343A (en) * | 1985-10-31 | 1987-03-31 | American Cyanamid Company | N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas |
| FR2601011B1 (fr) * | 1986-07-03 | 1988-10-28 | Sanofi Sa | Nouveaux derives tricycliques agonistes des recepteurs cholinergiques et medicaments en contenant |
| EP0351435B1 (en) * | 1987-11-02 | 1993-08-04 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused pyridazine compounds and their medicinal uses |
| PT93060B (pt) | 1989-02-07 | 1995-12-29 | Sanofi Sa | Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem |
| EP0628550B1 (en) | 1993-06-08 | 1998-02-25 | Sanofi | Pyridazines as interleukin-1beta converting enzyme inhibitors |
| US5484940A (en) * | 1994-11-28 | 1996-01-16 | Grant; Francine S. | Substituted 3-indolyl-5-pyrazolone compounds |
| GB9707693D0 (en) | 1997-04-16 | 1997-06-04 | Smithkline Beecham Plc | Novel method of treatment |
| TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
| US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
| EP1430033A4 (en) | 2001-08-31 | 2004-12-15 | Univ Northwestern | ANTI-INFLAMMATORY AND PROTEIN-INK-INHIBITING COMPOSITION AND THEIR USE |
| GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| CN1628109A (zh) * | 2002-02-05 | 2005-06-15 | 诺沃挪第克公司 | 新颖的芳基－与杂芳基－哌嗪 |
| FR2847253B1 (fr) | 2002-11-19 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant |
| US20040167226A1 (en) * | 2002-12-16 | 2004-08-26 | Serafini Tito A. | Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same |
| CA2532236C (en) * | 2003-07-29 | 2011-08-23 | Novo Nordisk A/S | Pyridazinyl- piperazines and their use as histamine h3 receptor ligands |
| TW200528455A (en) | 2003-12-19 | 2005-09-01 | Bristol Myers Squibb Co | Azabicyclic heterocycles as cannabinoid receptor modulators |
| PT1697370E (pt) | 2003-12-19 | 2007-05-31 | Bristol Myers Squibb Co | Heterociclos azabicíclicos como moduladores do receptor de canabinóides |
| US7220858B2 (en) * | 2003-12-23 | 2007-05-22 | Barbeau Pharma, Inc. | Synthesis of hydrazine and chlorinated derivatives of bicyclic pyridazines |
| MY145822A (en) * | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
| JP5337375B2 (ja) * | 2004-11-02 | 2013-11-06 | ノースウェスタン ユニバーシティ | ピリダジン化合物、組成物および方法 |
| WO2006050359A2 (en) * | 2004-11-02 | 2006-05-11 | Northwestern University | Pyridazine compounds and methods |
| WO2007127475A2 (en) | 2006-04-28 | 2007-11-08 | Northwestern University | Pyridazines for demyelinating diseases and neuropathic pain |
| CA2650711A1 (en) | 2006-04-28 | 2007-11-08 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
| WO2007130383A2 (en) | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions and treatments using pyridazine compounds and secretases |
| EP2015751A2 (en) | 2006-04-28 | 2009-01-21 | Northwestern University | Salts of pyridazine compounds |
| CA2650625A1 (en) | 2006-04-28 | 2007-11-08 | Northwestern University | Formulations containing pyridazine compounds for treating neuroinflammatory diseases |
| AU2008223066A1 (en) | 2007-03-02 | 2008-09-12 | Northwestern University | Compositions comprising derivatives of 3 -phenylpyridazine for treating seizure-related disorders |
-
2007
- 2007-04-27 CA CA002650625A patent/CA2650625A1/en not_active Abandoned
- 2007-04-27 MX MX2008013843A patent/MX2008013843A/es not_active Application Discontinuation
- 2007-04-27 CN CN200780023749A patent/CN101754762A/zh active Pending
- 2007-04-27 AU AU2007243280A patent/AU2007243280A1/en not_active Abandoned
- 2007-04-27 US US12/298,652 patent/US20090325973A1/en not_active Abandoned
- 2007-04-27 JP JP2009507823A patent/JP2009535344A/ja active Pending
- 2007-04-27 BR BRPI0710938-5A patent/BRPI0710938A2/pt not_active IP Right Cessation
- 2007-04-27 WO PCT/US2007/010248 patent/WO2007127375A2/en not_active Ceased
- 2007-04-27 EP EP07776351.4A patent/EP2063894B1/en active Active
-
2008
- 2008-10-28 IL IL194968A patent/IL194968A0/en unknown
-
2012
- 2012-10-25 US US13/660,671 patent/US9408845B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009535344A5 (enExample) | ||
| US8034808B2 (en) | Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine | |
| PH12021500049A1 (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors | |
| US10800775B2 (en) | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same | |
| US20240066042A1 (en) | Use of derivatives containing c-o-p bonds in patients with kidney failure | |
| SI2298768T1 (en) | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyridoS2,3-dCpyrimidine derivatives and related compounds for the treatment of cancer | |
| AU667527B2 (en) | Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and an S-phase or M-phase specific antineoplastic agent | |
| EP1857457A3 (en) | Benzimidazole derivative and its use as AII receptor antagonist | |
| WO2005097814A3 (en) | Composition and method for inhibiting platelet aggregation | |
| JP2013528652A5 (enExample) | ||
| MX378495B (es) | Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida. | |
| CY1110014T1 (el) | Παραγωγα τετραϋδροκαρβαζολιου χρησιμα ως τροποποιητες υποδοχεα ανδρογονων (sarm) | |
| MX340965B (es) | Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular. | |
| WO2008100447A3 (en) | Nucleoside analogs for antiviral treatment | |
| CA2469076A1 (en) | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses | |
| EP1334973A1 (en) | Preventive or therapeutic medicines for diabetes containing fused-heterocycle compounds or their salts | |
| JP2015500887A5 (enExample) | ||
| WO2007056232B1 (en) | Methods of using saha and bortezomib for treating cancer | |
| HU229076B1 (en) | Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties | |
| DE602007004851D1 (de) | A2a-adenosin-rezeptor-antagonisten | |
| BR0314126A (pt) | Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio | |
| EP2283835A3 (en) | Method and preparation for treating metabolic stress | |
| SK14732003A3 (sk) | Farmaceutická kompozícia obsahujúca antagonistu receptora P2T a ďalšie antitrombotické činidlo a jej použitie pri liečení trombózy | |
| JP2015522551A5 (enExample) | ||
| JP2017537886A5 (enExample) |